Chlamydia infections continue to pose a significant global challenge, affecting both human and animal health. At our company, we offer a comprehensive suite of services to support the development of chlamydia infection vaccines and therapeutics.
Overview of Chlamydia Infection
Chlamydia is a prevalent sexually transmitted infection caused by the obligate intracellular bacteria of the genus Chlamydia. The most common species responsible for human infections are Chlamydia trachomatis and Chlamydia pneumoniae. These pathogens can cause a wide range of clinical manifestations, from genital and respiratory tract infections to more severe complications like pelvic inflammatory disease, infertility, and pneumonia.
Fig. 1 Immune response processes during genital Chlamydia infection in mice. (Dockterman J., et al., 2021)
Vaccine Development for Chlamydia Infection
Developing an effective vaccine against chlamydia infections has proven to be a significant challenge, as the pathogen's unique biology and immune evasion strategies pose formidable obstacles. Researchers have systematically explored various vaccine approaches, including whole-cell, subunit, and live-attenuated strategies, to identify the most promising candidates.
One of the key successes in chlamydia vaccine development has been the development of a multivalent recombinant major outer membrane protein (rMOMP) vaccine for C. pecorum infections in koalas. Through a series of comprehensive vaccine trials, researchers have demonstrated the ability of this vaccine to induce robust and long-lasting humoral and cellular immune responses, reducing pathogen load and disease severity in this ecologically important host.
Therapeutics Development for Chlamydia Infection
Chlamydia infections have traditionally been treated with antibiotics, such as doxycycline, azithromycin, and erythromycin. However, the emergence of antibiotic resistance and the need for more effective and targeted therapies have driven the development of novel antimicrobial agents and adjunctive therapeutic strategies.
Table 1. Minimum inhibitory concentration (MIC) of selected antimicrobial agents against C. trachomatis and C. pneumoniae. (Kohlhoff S. A., et al., 2015)
| Antimicrobial |
C.trachomatis-MIC (µg/ml) |
C.pneumoniae-MIC (µg/ml) |
| Approved drugs |
| Doxycycline |
0.031-0.25 |
0.015-0.5 |
| Tigecycline |
0.03-0.125 |
0.125-0.25 |
| Erythromycin |
0.016-2 |
0.015-0.25 |
| Azithromycin |
0.6-2 |
0.05-0.25 |
| Clarithromycin |
0.015-0.125 |
0.004-0.125 |
| Clindamycin |
2-16 |
- |
| Ciprofloxacin |
0.5-2 |
1-4 |
| Levofloxacin |
0.12-0.5 |
0.25-1 |
| Moxifloxacin |
0.5-1 |
0.125-1 |
| Rifampin |
0.005-0.25 |
0.0075-0.03 |
| Trimethoprim |
≥128 |
≥128 |
| Sulfamethoxazole |
0.5-4 |
≥500 |
| Gentamicin |
500 |
500 |
| Vancomycin |
1000 |
1000 |
| Investigational drugs |
| Solithromycin (CEM-101) |
0.125-0.5 |
0.25-1 |
| Sitafloxacin |
0.031-0.063 |
0.031-0.125 |
| Nemonoxacin |
0.03-0.125 |
0.03-0.125 |
| Delafloxacin |
- |
0.06-0.125 |
| AZD0914 |
0.06-0.5 |
0.25-1 |
| Rifalazil |
0.00125-0.0025 |
0.00125 |
Our Services
At our company, we are dedicated to advancing the fight against Chlamydia infections through our comprehensive suite of vaccine and therapy development services. Our experienced team of scientists, immunologists, microbiologists, and drug discovery experts work in close collaboration to provide end-to-end solutions for our clients.
- Mouse Models (C.muridarum)
- Guinea Pig Models (C.caviae)
- Non-Human Primate (NHP) Models
- Pig-Tailed Macaque Models
- Baboon Models (Papio anubis)
- Human chlamydia trachomatis in Mice
Whether you are a biotechnology startup, a pharmaceutical company, or a research institution, we can support your chlamydia-related projects at every stage, from target identification and candidate selection to preclinical validation. Our team of experts is committed to providing high-quality data and insights to accelerate the development of groundbreaking Chlamydia interventions. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
References
- Dockterman Jacob, and Jörn Coers. "Immunopathogenesis of genital Chlamydia infection: insights from mouse models." Pathogens and Disease 79.4 (2021): ftab012.
- Kohlhoff, Stephan A., and Margaret R. Hammerschlag. "Treatment of Chlamydial infections: 2014 update." Expert opinion on pharmacotherapy 16.2 (2015): 205-212.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
